Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein

@article{Cooney1991SafetyOA,
  title={Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein},
  author={E. Cooney and A. Collier and P. Greenberg and R. Coombs and J. Zarling and D. Arditti and M. Hoffman and S-L. Hu and L. Corey},
  journal={The Lancet},
  year={1991},
  volume={337},
  pages={567-572}
}
In a randomised phase I trial of a recombinant vaccina virus vaccine expressing the gp160 envelope gene of the human immunodeficiency virus (HIVAC-1e) 35 healthy, HIV-seronegative males, 31 of whom had a history of smallpox immunisation and 4 of whom were vaccinia naive, were vaccinated and then boosted 8 weeks later with HIVAC-1e or standard NY strain vaccinia virus. The frequency, duration, and titre of virus isolation from the vaccination site and occurrence of local side-effects were… Expand
Human studies in the development of human immunodeficiency virus vaccines.
  • R. Dolin
  • Biology, Medicine
  • The Journal of infectious diseases
  • 1995
Subcutaneous Administration of a Recombinant Vaccinia Virus Vaccine Expressing Multiple Envelopes of HIV-1
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 19 REFERENCES
Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120.
  • P. Berman, J. Groopman, +7 authors L. Lasky
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 1988
...
1
2
...